Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

For Patrick Flanagan, CEO of Veristat, optimism will drive new financial growth.“The coming year will mark a new era of ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson's disease. The results of the phase 2 ...

Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS), a rare and life-threatening inherited disease. The Italian non-profit ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic dysfunction-associated steatohepatitis (MASH) to help measure disease activity.

Less than two years after buying Chinese biotech Gracell for its cell therapy platform, AstraZeneca has reported encouraging clinical results with the lead CAR-T from the deal, GC012F (now AZD0120), ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...

UK Health Secretary Wes Streeting has given the green light to a series of NHS reforms that will see around 18,000 administrative roles abolished, following a deal with the Treasury. Streeting has ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site to ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening early ...

NHS England has awarded a new contract to US data analytics company Palantir to transition existing NHS projects into a new federated data platform (FDP), prompting pushback from organisations unhappy ...

Brain-computer interface (BCI) developer Neuralink has completed a $650 million fifth-round financing that the company says will allow it to "bring our technology to more people." The injection of ...